NIAID Panels Review Grants for Disease Research Funding
Published Date: 7/17/2025
Notice
Summary
The National Institute of Allergy and Infectious Diseases is holding public and private meetings on September 25, 2025, to review grant applications and share important updates. Scientists, researchers, and grant applicants will be affected as funding decisions and reports from top leaders are discussed. The open sessions will be streamed online, making it easy for anyone interested to tune in and stay informed.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
NIAID to Review Grant Applications
If you are a scientist, researcher, or grant applicant, NIAID will hold closed sessions on September 25, 2025 from 8:30 a.m. to 10:30 a.m. to review and evaluate grant applications; funding decisions and application discussions will occur during that time.
Open Sessions Videocast for Public
You can watch the NIAID open sessions online: on September 25, 2025 the Council open session is scheduled 10:30 a.m. to 11:45 a.m., and several subcommittee open sessions run 1:00 p.m. to mid- or late-afternoon; the open sessions will be videocast at http://videocast.nih.gov.
Closed Sessions Protect Confidential Information
NIAID will close portions of the meetings (per 5 U.S.C. 552b(c)(4) and (c)(6)) because grant discussions could disclose confidential trade secrets, patentable material, or personal information; those sensitive details will not be public.
Accommodations Available for Attendees
If you plan to attend and need special assistance (for example, sign language interpretation), you should notify the contact person (Kelly Y. Poe, Ph.D., (240) 669-5036 or [email protected]) in advance of the September 25, 2025 meeting so reasonable accommodations can be arranged.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-13434, National Institute of Allergy and Infectious Diseases; Notice of Meeting
The National Institute of Allergy and Infectious Diseases is holding a public meeting on September 25, 2025, to discuss the latest updates on AIDS research. Anyone interested can watch online, and special accommodations are available if requested ahead of time. This meeting helps guide important health research and keeps the public in the loop without any cost to attend.
Next: 2025-13436, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding two closed virtual meetings in August 2025 to review important grant applications in neuroscience and transplant immunology. These meetings keep sensitive info private to protect personal and commercial secrets. Researchers applying for grants should note the dates and prepare, as these reviews impact funding decisions.